Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer Patients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Aug 6

PMID 27494141

Citations 6

Authors

Danny T M Leung

Pak-Leong Lim

Tak-Hong Cheung

Raymond R Y Wong

So-Fan Yim

Margaret H L Ng

Frankie C H Tam

Tony K H Chung

Yick-Fu Wong

Affiliations

Soon will be listed here.

Abstract

We investigated whether circulating osteopontin (OPN) could be used as a biomarker for cervical cancer. We employed a monoclonal antibody (mAb 659) specific for the unique and intact thrombin-sensitive site in OPN using an inhibition ELISA. We found significantly higher levels of OPN in 33 cervical cancer patients in both the plasma (mean +/- SD, 612 +/- 106 ng/mL) and serum (424 +/- 121 ng/mL) compared to healthy subjects [409 +/- 56 ng/mL, from 31 plasma samples (P < 0.0001), and 314 +/- 98 ng/mL, from 32 serum samples (P = 0.0002), respectively]. Similar results were obtained when the plasma from a bigger group (147 individuals) of cervical cancer patients (560 +/- 211 ng/mL) were compared with the same plasma samples of the healthy individuals (P = 0.0014). More significantly, the OPN level was highest in stage III-IV disease (614 +/- 210 ng/mL, from 52 individuals; P = 0.0001) and least and non-discriminatory in stage I (473 +/- 110 ng/mL, from 40 individuals; P = 0.5318). No such discrimination was found when a mAb of a different specificity (mAb 446) was used in a similar inhibition ELISA to compare the two groups in the first study; a commercial capture ELISA also failed. The possibility that the target epitope recognized by the antibody probe in these assays was absent from the circulating OPN due to protein truncation was supported by gel fractionation of the OPN found in patients' plasma: 60-64 kDa fragments were found instead of the presumably full-length OPN (68 kDa) seen in healthy people. How these fragments are generated and what possible role they play in cancer biology remain interesting questions.

Citing Articles

Endocrine regulation and metabolic mechanisms of osteopontin in the development and progression of osteosarcoma, metastasis and prognosis.

Shao Z, Bi S Front Endocrinol (Lausanne). 2023; 13:1100063.

PMID: 36714568 PMC: 9880040. DOI: 10.3389/fendo.2022.1100063.

Biological and Clinicopathological Characteristics of OPN in Cervical Cancers.

Qin S, Yi L, Liang Y, Chen Y, Wang W, Liao Y Front Genet. 2022; 13:836509.

PMID: 35669197 PMC: 9163571. DOI: 10.3389/fgene.2022.836509.

The of osteopontin in nervous system diseases: damage repair.

Cappellano G, Vecchio D, Magistrelli L, Clemente N, Raineri D, Mazzucca C Neural Regen Res. 2020; 16(6):1131-1137.

PMID: 33269761 PMC: 8224140. DOI: 10.4103/1673-5374.300328.

Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis.

Laniewski P, Cui H, Roe D, Barnes D, Goulder A, Monk B Sci Rep. 2019; 9(1):7333.

PMID: 31089160 PMC: 6517407. DOI: 10.1038/s41598-019-43849-5.

Osteopontin as a biomarker for osteosarcoma therapy and prognosis.

Han X, Wang W, He J, Jiang L, Li X Oncol Lett. 2019; 17(3):2592-2598.

PMID: 30854034 PMC: 6365895. DOI: 10.3892/ol.2019.9905.

References

Christensen B, Nielsen M, Haselmann K, Petersen T, Sorensen E . Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J. 2005; 390(Pt 1):285-92. PMC: 1184582. DOI: 10.1042/BJ20050341. View

Song J, Lee J, Lee N, Yeom B, Kim S, Lee K . Osteopontin expression correlates with invasiveness in cervical cancer. Aust N Z J Obstet Gynaecol. 2009; 49(4):434-8. DOI: 10.1111/j.1479-828X.2009.01027.x. View

Wun H, Leung D, Wong K, Chui Y, Lim P . Molecular mimicry: anti-DNA antibodies may arise inadvertently as a response to antibodies generated to microorganisms. Int Immunol. 2001; 13(9):1099-107. DOI: 10.1093/intimm/13.9.1099. View

Leung D, van Maren W, Chan F, Chan W, Lo A, Ma C . Extremely low exposure of a community to severe acute respiratory syndrome coronavirus: false seropositivity due to use of bacterially derived antigens. J Virol. 2006; 80(18):8920-8. PMC: 1563915. DOI: 10.1128/JVI.00649-06. View

Castellano G, Malaponte G, Mazzarino M, Figini M, Marchese F, Gangemi P . Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res. 2008; 14(22):7470-80. DOI: 10.1158/1078-0432.CCR-08-0870. View

Kazanecki C, Uzwiak D, Denhardt D . Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007; 102(4):912-24. DOI: 10.1002/jcb.21558. View

Yan M, Tam F, Kan B, Lim P . Combined rapid (TUBEX) test for typhoid-paratyphoid A fever based on strong anti-O12 response: design and critical assessment of sensitivity. PLoS One. 2011; 6(9):e24743. PMC: 3174194. DOI: 10.1371/journal.pone.0024743. View

Leung D, Tam F, Ma C, Chan P, Cheung J, Niu H . Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis. 2004; 190(2):379-86. PMC: 7110057. DOI: 10.1086/422040. View

Sakaguchi H, Fujimoto J, Hong B, Tamaya T . Clinical implications of osteopontin in metastatic lesions of uterine cervical cancers. Cancer Lett. 2006; 247(1):98-102. DOI: 10.1016/j.canlet.2006.03.026. View

10.

Oldberg A, Franzen A, Heinegard D . Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A. 1986; 83(23):8819-23. PMC: 387024. DOI: 10.1073/pnas.83.23.8819. View

11.

Agnihotri R, Crawford H, Haro H, Matrisian L, Havrda M, Liaw L . Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem. 2001; 276(30):28261-7. DOI: 10.1074/jbc.M103608200. View

12.

Thoms J, Dal Pra A, Anborgh P, Christensen E, Fleshner N, Menard C . Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer. 2012; 107(5):840-6. PMC: 3425969. DOI: 10.1038/bjc.2012.345. View

13.

Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang X . An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007; 26(44):6361-71. DOI: 10.1038/sj.onc.1210463. View

14.

Shinohara M, Cantor H . The bridge between dendritic cells and asthma. Nat Med. 2007; 13(5):536-8. DOI: 10.1038/nm0507-536. View

15.

Kon S, Ikesue M, Kimura C, Aoki M, Nakayama Y, Saito Y . Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J Exp Med. 2007; 205(1):25-33. PMC: 2234375. DOI: 10.1084/jem.20071324. View

16.

Lim A, Rischin D, Fisher R, Cao H, Kwok K, Truong D . Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res. 2011; 18(1):301-7. PMC: 3251655. DOI: 10.1158/1078-0432.CCR-11-2295. View

17.

Teramoto H, Castellone M, Malek R, Letwin N, Frank B, Gutkind J . Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene. 2004; 24(3):489-501. DOI: 10.1038/sj.onc.1208209. View

18.

Giachelli C, Speer M, Li X, Rajachar R, Yang H . Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005; 96(7):717-22. DOI: 10.1161/01.RES.0000161997.24797.c0. View

19.

Le Q, Sutphin P, Raychaudhuri S, Yu S, Terris D, Lin H . Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003; 9(1):59-67. View

20.

Bellahcene A, Castronovo V, Ogbureke K, Fisher L, Fedarko N . Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 2008; 8(3):212-26. PMC: 2484121. DOI: 10.1038/nrc2345. View